Quantitative Concept – Page 13

Beyond Theory: Real-World AI Wins in Life Science R&D – Faster & Smarter

5 months ago talkbio0Tagged Artificial Intelligence, Biological Science Disciplines, Clinical Trials, Drug Discovery, Efficiency, Financial cost, Infrequent, R&D, trends qualifier

AI in life sciences; R&D efficiency; drug discovery; clinical trials; pharma innovation; 2025 AI trends; cost reduction; rare diseases

Senate Drops Orphan Cures Act from Trump’s Tax Bill, Dealing Setback to Biopharma

5 months ago talkbio0Tagged Beak, Big Beautiful Bill, Biopharma, Drugs, Orphan, healthcare legislation, Infrequent, Ira (eukaryote), Mediation, Orphan Cures Act, Prices, reconciliation, Senate, Transplant Registry Unified Management Program

Orphan Cures Act; orphan drugs; Trump tax bill; biopharma; Senate; IRA price negotiations; rare diseases; Big Beautiful Bill; healthcare legislation; reconciliation bill

Lilly Makes All Zepbound Doses Available via Direct Pay Program

5 months ago talkbio0Tagged Availability of, Dosage, eli lilly, LillyDirect, Obesity, pharmacy platform, Zepbound

Zepbound; Eli Lilly; direct pay; LillyDirect; tirzepatide; obesity medication; dose availability; pharmacy platform

UCB Announces Major Investment to Expand US Biologics Manufacturing Capacity

5 months ago talkbio0Tagged Biological Factors, biomanufacturing, economic impact, expansion, Investments, Manufacturing, U.S., UCB

UCB; biologics manufacturing; US expansion; biomanufacturing; biopharmaceutical; investment; jobs; economic impact

FDA Reinstates Generic Drug Policy Group After April Firings

5 months ago talkbio0Tagged Administrative action, Departure - action, development aspects, drug price, Generic Drugs, layoffs, Office, Policy, reinstatement, Transection (procedure), United States Food and Drug Administration

FDA; generic drugs; policy office; Division of Policy Development; reinstatement; layoffs; drug prices; administrative leave

Federally-Funded Cancer Research at a Perilous Crossroads: Deep Cuts Threaten Progress

5 months ago talkbio0Tagged AACR, Budgets, Cancer Research, Congress (U.S. Legislature), federal, Funding, Malignant neoplasm of lung, NIH Mouse, Pancreatic carcinoma, public health policy

federal funding; cancer research; NIH budget cuts; Congress; lung cancer; pancreatic cancer; AACR; public health policy

Corcept Highlights Survival Benefit Despite ALS Trial’s Missed Primary Endpoint

5 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Benefit, Corcept, DAZALS trial, dazucorilant, Phase 2 Clinical Trials, SURVEY.ALSFRSR, Survival

Corcept Therapeutics; dazucorilant; ALS; amyotrophic lateral sclerosis; DAZALS trial; survival benefit; phase 2 study; ALSFRS-R; ENCALS 2025

Gilead Bolsters Trodelvy in Triple-Negative Breast Cancer With Practice-Changing Keytruda Combo Win

5 months ago talkbio0Tagged Antibody-Drug Conjugates, Combined Modality Therapy, Gilead Sciences, Immunotherapy, Keytruda, Phase 3 trial, practice-changing, Progression-Free Survival, TNBC, Triple Negative Breast Neoplasms, Trodelvy

Gilead Sciences; Trodelvy; Keytruda; triple-negative breast cancer; TNBC; antibody-drug conjugate; immunotherapy; progression-free survival; ASCO 2025; phase 3 trial; practice-changing; combination therapy